{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:49:21Z","timestamp":1784836161695,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001697","name":"Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15693"],"award-info":[{"award-number":["22K15693"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10606"],"award-info":[{"award-number":["24K10606"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jns.2026.125751","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:15:03Z","timestamp":1767831303000},"page":"125751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine"],"prefix":"10.1016","volume":"481","author":[{"given":"Shungo","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125751_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105900","article-title":"Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis","volume":"195","author":"Alasad","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"4","key":"10.1016\/j.jns.2026.125751_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11916-025-01365-4","article-title":"Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine","volume":"29","author":"Nicol","year":"2025","journal-title":"Curr. Pain Headache Rep."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J. Headache Pain"},{"issue":"4","key":"10.1016\/j.jns.2026.125751_bb0025","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume":"45","author":"Ornello","year":"2025","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.jns.2026.125751_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070934","article-title":"A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response","volume":"16","author":"Hong","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.jns.2026.125751_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231177649","article-title":"Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan","volume":"43","author":"Suzuki","year":"2023","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.jns.2026.125751_bb0040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/pm\/pnae050","article-title":"Effectiveness of fremanezumab treatment in patients with migraine headache","volume":"25","author":"Kikui","year":"2024","journal-title":"Pain Med."},{"issue":"3","key":"10.1016\/j.jns.2026.125751_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030734","article-title":"One-year compliance after calcitonin gene-related peptide monoclonal antibody therapy for migraine patients in a real-world setting: a multicenter cross-sectional study","volume":"14","author":"Kang","year":"2025","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.jns.2026.125751_bb0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2169\/internalmedicine.4037-24","article-title":"Real-world efficacy of erenumab on migraine-associated symptoms and patient-reported satisfaction levels: a retrospective study in Japan","volume":"64","author":"Ihara","year":"2025","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","article-title":"Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study","volume":"24","author":"Ihara","year":"2023","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12883-023-03449-3","article-title":"Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study","volume":"23","author":"Ohtani","year":"2023","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","article-title":"Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis","volume":"22","author":"Takizawa","year":"2022","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0070","article-title":"Predictors of galcanezumab response in a real-world study of Korean patients with migraine","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jns.2026.125751_bb0075","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00415-023-11788-x","article-title":"Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study","volume":"270","author":"Suzuki","year":"2023","journal-title":"J Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.125751_bb0080","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10072-023-06683-2","article-title":"Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study","volume":"44","author":"Lee","year":"2023","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12883-023-03521-y","article-title":"Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers","volume":"24","author":"Shibata","year":"2024","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s10194-024-01756-9","article-title":"Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR)","volume":"25","author":"Sharp","year":"2024","journal-title":"J. Headache Pain"},{"issue":"7","key":"10.1016\/j.jns.2026.125751_bb0095","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/head.13330","article-title":"Patients with migraine have substantial reductions in measures of visual quality of life","volume":"58","author":"Hanson","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.jns.2026.125751_bb0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/JPR.S124683","article-title":"Humanistic and economic burden of nausea and vomiting among migraine sufferers","volume":"10","author":"Gajria","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.jns.2026.125751_bb0105","series-title":"Panminerva Medica 20th World Congress on Psychosomatic Medicine. Abstract Book","first-page":"79","article-title":"Validation and utility of a Japanese version of the GAD-7","author":"Muramatsu","year":"2009"},{"key":"10.1016\/j.jns.2026.125751_bb0110","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3389\/fpsyg.2018.01741","article-title":"Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status","volume":"9","author":"Doi","year":"2018","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jns.2026.125751_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.genhosppsych.2018.03.007","article-title":"Performance of the Japanese version of the patient health questionnaire-9 (J-PHQ-9) for depression in primary care","volume":"52","author":"Muramatsu","year":"2018","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2026.125751_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ncn3.70042","article-title":"Clinical practice guideline for headache disorders 2021","volume":"13","author":"Araki","year":"2025","journal-title":"Neurol. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","article-title":"Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan","volume":"25","author":"Takizawa","year":"2024","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0130","first-page":"1","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.jns.2026.125751_bb0135","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4300\/JGME-5-4-18","article-title":"Analyzing and interpreting data from Likert-type scales","volume":"5","author":"Sullivan","year":"2013","journal-title":"J. Grad. Med. Educ."},{"issue":"4","key":"10.1016\/j.jns.2026.125751_bb0140","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s10072-023-07241-6","article-title":"Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study","volume":"45","author":"Braca","year":"2024","journal-title":"Neurol. Sci."},{"issue":"13","key":"10.1016\/j.jns.2026.125751_bb0145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/03331024221111526","article-title":"Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine","volume":"42","author":"Iannone","year":"2022","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","article-title":"Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany","volume":"22","author":"Straube","year":"2021","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-023-01560-x","article-title":"Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders","volume":"24","author":"Ashina","year":"2023","journal-title":"J. Headache Pain"},{"issue":"9","key":"10.1016\/j.jns.2026.125751_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241281518","article-title":"Are we closer to achieving precision medicine for migraine treatment? A narrative review","volume":"44","author":"Ihara","year":"2024","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.jns.2026.125751_bb0165","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/ene.15458","article-title":"Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: a multicenter Spanish study","volume":"29","author":"Gonzalez-Martinez","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.125751_bb0170","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/head.14233","article-title":"Timing and durability of response to erenumab in patients with episodic migraine","volume":"61","author":"McAllister","year":"2021","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.jns.2026.125751_bb0175","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/head.14193","article-title":"Timing and durability of response to erenumab in patients with chronic migraine","volume":"61","author":"Tepper","year":"2021","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.jns.2026.125751_bb0180","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","article-title":"Ultra-late response (>24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study","volume":"271","author":"Barbanti","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.125751_bb0185","first-page":"11","article-title":"Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study","author":"Basedau","year":"2022","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.jns.2026.125751_bb0190","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231212895","article-title":"Targeting CGRP pathways and aura: a peripheral site with a central effect","volume":"43","author":"Al-Karagholi","year":"2023","journal-title":"Cephalalgia"},{"issue":"46","key":"10.1016\/j.jns.2026.125751_bb0195","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.1073\/pnas.1215435109","article-title":"Critical role of calcitonin gene-related peptide receptors in cortical spreading depression","volume":"109","author":"Tozzi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.jns.2026.125751_bb0200","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/j.pain.0000000000001791","article-title":"Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier","volume":"161","author":"Melo-Carrillo","year":"2020","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s10194-025-02127-8","article-title":"Small-molecule CGRP antagonist atogepant does not affect cortical spreading depression susceptibility in rats","volume":"26","author":"Jin","year":"2025","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-025-02012-4","article-title":"Is there a role of calcitonin gene-related peptide in cortical spreading depression mechanisms?- argument con","volume":"26","author":"Melo-Carrillo","year":"2025","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.125751_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10194-024-01737-y","article-title":"CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society","volume":"25","author":"Takizawa","year":"2024","journal-title":"J. Headache Pain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:24:31Z","timestamp":1774275871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"alternative-id":["S0022510X26000328"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125751","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125751"}}